Compare Norfolk Southern Corporation (NSC) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Norfolk Southern Corporation vs State Street SPDR S&P Biotech ETF — how do they compare? Norfolk Southern Corporation trades at $335.84 (market cap $75.15B), while State Street SPDR S&P Biotech ETF trades at $159.35. The key difference: Norfolk Southern Corporation pays a 1.61% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Norfolk Southern Corporation nearer its low. Which is the better fit depends on your goals.
| NSC | XBI | |
|---|---|---|
Market Cap | $75.15B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $350.66 | $164.28 |
52-Week Low | $272.35 | $86.92 |
Enterprise Value | $90.70B | — |
Dividend Yield | 1.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Norfolk Southern (NSC) trades at $334.44, up 0.15% on the day, with a bullish technical signal supported by moving averages. The stock shows strong fundamentals, including three consecutive quarterly earnings beats, a net income margin of 21.02%, and robust cash flow from operations of $4.36B in 2025. Recent news highlights merger developments with Union Pacific and positive Q2 2026 results driven by freight demand.
Outlook is positive with a consensus price target of $369.67, implying upside, but risks include high valuation (P/E 28.55), merger regulatory scrutiny, and fuel cost pressures. Institutional sentiment is mixed with 43.75% buy ratings, yet hedge fund activity suggests potential momentum.
XBI trades at $158.81, up 0.49% today, with a bullish technical signal supported by moving averages. The ETF shows strong momentum with a 17% monthly gain and 75% annual return, driven by biotech sector strength. Analyst coverage is limited to one hold rating, while recent news highlights institutional buying interest and positive sector developments including M&A activity and drug trial successes.
The outlook remains positive given biotech's breakout from multi-year bear markets, though elevated volatility and policy risks persist. Key opportunities include AI-driven drug discovery and sustained M&A momentum, while risks involve sector-specific volatility and regulatory uncertainty. The ETF's equal-weight approach provides diversified exposure to biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Norfolk Southern Corporation
Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.
Read more on NSC →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
